Nanotechnology-based therapeutics: new hope for ischemic cerebral stroke intervention  

作　　者：Sihan Wang Qiming Gao Fuyao Xiao Yuming Zhao 

机构地区：[1]Department of Pharmacology,School of Basic Medical Sciences,Capital Medical University,Beijing 100069,China

出　　处：《Journal of Translational Neuroscience》2020年第1期8-17,共10页转化神经科学电子杂志（英文）

摘　　要：Ischemic cerebral stroke is a leading cause of death and disability globally.At present,thrombolytics,such as recombinant tissue-type plasminogen activator,are the only effective treatment for acute stroke.However,usage of thrombolytics has a strict therapeutic window and cannot be applied to a number of patients.Despite the promising effects of some neuroprotectants in preclinical studies,they failed in clinical trials as a result of poor pharmacokinetic properties,particularly with regard to solubility and permeability across the blood-brain barrier(BBB).Approaches for delivering these drugs by nanotechnologies may overcome these pharmacokinetic deficits and enhance their neuroprotective effects.However,issues such as potential side effects and biosafety properties currently limit clinical application of these approaches.In this article,we reviewed recent progress of nanotechnology-based interventions for stroke treatment,and in particular,summarized novel materials applied to synthesize nanocarriers,encapsulation with neuroprotectants,and factors impacting nanodrug bioactivities to provide a theoretical basis for the development of anti-stroke drugs.

关 键 词：ischemic cerebral stroke blood-brain barrier(BBB) nanoparticles drug delivery NEUROPROTECTION 

分 类 号：R74[医药卫生—神经病学与精神病学]